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The precision of subtyping assays 
is a matter of importance and debate 
for epidemiologic and, recently, fo-
rensic investigations. Strain identity 
is commonly used to infer a common 
source even when spatial and tempo-
ral data are not congruent. Moreover, 
the deﬁ  nition of a strain is somewhat 
unclear and relies on analytical meth-
ods that vary widely. Therefore, iso-
lates may be erroneously excluded or 
included into a strain deﬁ  nition and 
disease outbreak as illustrated with 
the Ames strain and 2 contrasting ap-
proaches to identiﬁ  cation.  MLVA15 
ties naturally occurring isolates to 
bioterrorism-associated attacks, while 
speciﬁ   c SNP assays can distinguish 
among them.
MLVA is an unbiased approach 
and can be used on any set of B. an-
thracis strains, although, as in the 
2006 and 2007 Texas outbreaks, it 
can be limited in resolving power. In 
contrast, our SNP assays have great 
resolving power but are useful only 
for differentiating the Ames strain, 
thus limiting their value to categorical 
inclusion or exclusion in outbreaks. 
Future rational use of a battery of dif-
ferent molecular signatures will yield 
far greater insights into strain iden-
tity than the application of 1 speciﬁ  c 
signature.
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Bluetongue in 
Eurasian Lynx
To the Editor: Bluetongue is an 
infectious disease of ruminants; it is 
caused by bluetongue virus (BTV), 
has 24 known serotypes, and is trans-
mitted by several species of Culi-
coides biting midges. The disease 
mainly affects sheep and occurs when 
susceptible animals are introduced to 
areas where BTV circulates or when 
BTV is introduced to naive ruminant 
populations. The natural host range is 
strictly limited to ruminants, although 
seroconversion without disease has 
been reported in carnivores (1). We re-
port BTV infection, disease, and death 
in 2 Eurasian lynx (Lynx lynx) and the 
isolation of BTV serotype 8 (BTV-8) 
from this carnivorous species.
 The 2 Eurasian lynx, held in the 
same cage in a zoo in Belgium, became 
lethargic in September 2007; animal 1 
died after 2 days, and animal 2 died in 
February 2008. Both had been fed ru-
minant fetuses and stillborns from sur-LETTERS
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008  1497 
rounding farms in an area where many 
bluetongue cases had been conﬁ  rmed 
(2). Necropsy ﬁ   ndings for animal 1 
were anemia, subcutaneous hemato-
mas, petechial hemorrhages, and lung 
congestion with edema. Necropsy 
ﬁ   ndings for animal 2 were emacia-
tion, anemia, enlarged and gelatinous 
lymph nodes, petechial hemorrhages, 
and pneumonia. For each animal, mi-
croscopic examination showed edem-
atous vascular walls; enlarged en-
dothelial cells; and evidence of acute 
to subacute vasculitis in muscle, myo-
cardium, peritoneum, and lung. Tissue 
samples (spleen, lung, intestine) were 
analyzed by using 2 real-time reverse 
transcriptase–quantitative PCR tech-
niques targeting BTV segment 5 and 
host β-actin mRNA as a control. BTV 
RNA was found in all samples from 
animal 1; cycle threshold values (3) 
ranged from 28.6 to 36.2. Tissues from 
animal 2 were negative for BTV RNA. 
Although the internal control was 
originally designed to detect β-actin 
mRNA of bovine or ovine species, 
clear positive signals were noted in 
all lynx samples, which indicated that 
this was a reliable control procedure. 
Infectious virus was subsequently iso-
lated from the lung sample of animal 
1 after inoculation of embryonated 
chicken eggs and ampliﬁ  cation  in 
baby hamster kidney–21 cell cultures 
(4). The speciﬁ  city of the cytopathic 
effect, observed 48 hours after pas-
sage on baby hamster kidney–21 cells, 
was conﬁ   rmed by real-time reverse 
transcriptase–quantitative PCR. Virus 
neutralization using speciﬁ  c reference 
serum (5) proved that the isolated vi-
rus was BTV-8. Anti-BTV antibod-
ies were detected in lung tissue ﬂ  uid 
from animal 2 (ID Screen Bluetongue 
Competition assay, ID VET, Monpel-
lier, France) (6).
We describe a natural, wild-type 
infection of a carnivorous species. Al-
though deaths have been documented 
in dogs accidentally infected with a 
BTV-contaminated vaccine (7), the 2 
lynx in this report were neither vacci-
nated nor medically treated by injec-
tion. BTV-8 was ﬁ   rst introduced to 
northern Europe in 2006 and has sub-
sequently spread rapidly to many coun-
tries on that continent. During 2007, a 
total of 6,870 bluetongue cases were 
reported in Belgium (2); animal 1 died 
in September 2007, which correspond-
ed to the peak of bluetongue outbreaks 
in that region. No deaths were report-
ed during that period among other ani-
mals, including ruminants, held in the 
same zoo as the 2 lynx reported here. 
The time lapse between initial clinical 
signs and death could explain the fail-
ure to detect BTV-8 RNA in animal 2. 
Although speculative, the suspicion of 
bluetongue in this animal is based on 
the presence of anti–BTV-8 antibod-
ies, vasculitis, and pneumonia, which 
have been found in dogs accidentally 
infected with BTV (7).
This report raises questions about 
the current knowledge of the epide-
miology of bluetongue. Bluetongue in 
lynx indicates that the list of known 
susceptible species must be widened, at 
least for serotype 8. Although infection 
of a susceptible host by an insect vector 
is the only proven natural transmission 
mechanism for wild-type BTV, transpla-
cental transmission of BTV-8, resulting 
in the birth of seropositive (8) or virus-
positive calves (9), has recently been 
described in cattle. Although infection 
by an insect vector cannot be excluded, 
transmission by the oral route must be 
strongly suspected because the lynx 
described in this report had been fed 
ruminant fetuses and stillborn animals 
from surrounding farms. This possibil-
ity is supported by a previous suspicion 
that seroconversion to BTV in carni-
vores was a result of oral infection (1). 
The possibility of oral transmission is 
also supported by evidence of lateral 
transmission of BTV infection to cattle 
having occurred, in the absence of in-
sect vectors, as a result of direct contact 
with newborn viremic calves born to 
infected dams that had been imported 
to Northern Ireland from a bluetongue-
infected region of continental Europe 
(S. Kennedy, unpub. data). The role of 
wildlife, especially carnivores, in the 
epidemiology of bluetongue deserves 
further study to elucidate their role as 
either dead-end hosts or new sources 
of infection for livestock and to help 
determine the risks for wildlife popula-
tions. 
Our ﬁ  ndings clearly indicate that 
a novel transmission pathway enables 
the virus to cross species. Conse-
quently, transmission to other species, 
including domestic animals, can no 
longer be excluded. Moreover, oral 
transmission is likely to have consid-
erable implications for disease control, 
including vaccination, because BTV-8 
is a fast-emerging virus with major ﬁ  -
nancial consequences.
Acknowledgment
We thank M. Sarlet for technical help.
Thierry P. Jauniaux, 
Kris E. De Clercq, 
Dominique E. Cassart, 
Seamus Kennedy, 
Frank E. Vandenbussche, 
Elise L. Vandemeulebroucke, 
Tine M. Vanbinst, 
Bart I. Verheyden, 
Nesya E. Goris, 
and Freddy L. Coignoul
Author afﬁ   liations: Royal Belgian Institute 
of Natural Sciences, Brussels, Belgium 
(T.P. Jauniaux); University of Liege, Liege, 
Belgium (T.P. Jauniaux, D.E. Cassart, F.L. 
Coignoul); Veterinary and Agrochemi-
cal Research Centre, Brussels (K.E. De 
Clercq, F.E. Vandenbussche, E.L. Vande-
meulebroucke, T.M. Vanbinst, B.I. Verhey-
den, N.E. Goris); and Agri-Food and Biosci-
ences Institute, Belfast, Northern Ireland, 
UK (S. Kennedy)
DOI: 10.3201/eid1409.080434
References
  1.   Alexander KA, MacLachlan NJ, Kat PW, 
House C, O’Brien SJ, Lerche NW, et al. 
Evidence of natural bluetongue virus in-
fection among African carnivores. Am J 
Trop Med Hyg. 1994;51:568–76.LETTERS
1498  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008
    2.   Federal Agency for the Safety of the 
Food Chain. Epidemiological situa-
tion of the bluetongue in Belgium [cited 
2008 Jan 25]. Available from http://www.
afsca.be/crisis/sa-blueT/doc07/2008-01-
25_KAART_v65_bis.pdf 
  3.   Toussaint JF, Sailleau C, Bréard E, Zien-
tara S, De Clercq K. Bluetongue virus 
detection by two real-time RT-qPCRs tar-
geting two different genomic segments. J 
Virol Methods. 2007;140:115–23. DOI: 
10.1016/j.jviromet.2006.11.007
  4.   Bréard E, Sailleau C, Coupier H, Mure-
Ravaud K, Hammoumi S, Gicquel B, et al. 
Comparison of genome segments 2, 7 and 
10 of bluetongue viruses serotype 2 for 
differentiation between ﬁ  eld isolates and 
the vaccine strain. Vet Res. 2003;34:777–
89. DOI: 10.1051/vetres:2003036
  5.   Toussaint JF, Sailleau C, Mast J, Houdart 
P, Czaplicki G, Demeestere L, et al. Blu-
etongue in Belgium, 2006. Emerg Infect 
Dis. 2007;13:614–6 [cited 2008 Jan 25]. 
Available from http://www.cdc.gov/eid/
content/13/4/614.htm
  6.   Vandenbussche F, Vanbinst T, Verheyden 
B, van Dessel W, Demeestere L, Houdart 
P, et al. Evaluation of antibody-ELISA 
and real-time RT-PCR for the diagnosis 
and proﬁ   ling of bluetongue virus sero-
type 8 during the epidemic in Belgium 
in 2006. Vet Microbiol. 2008;129:15–27. 
10.1016/j.vetmic.2007.10.029.
  7.   Evermann JF, McKeiman AJ, Wilbur LA, 
Levings RL, Trueblood ES, Baldwin TJ, 
et al. Canine facilities associated with the 
use of a modiﬁ  ed live vaccine adminis-
tered during late stages of pregnancy. J Vet 
Diagn Invest. 1994;6:353–7.
  8.   Desmecht D, Bergh RV, Sartelet A, Leclerc 
M, Mignot C, Misse F, et al. Evidence for 
transplacental transmission of the current 
wild-type strain of bluetongue virus sero-
type 8 in cattle. Vet Rec. 2008;163:50-2.
  9.   Wouda W, Roumen M, Peperkamp N, Vos 
J, van Garderen E, Muskens J. Hydranen-
cephaly in calves following the bluetongue 
serotype 8 epidemic in the Netherlands. 
Vet Rec. 2008;162:422–3.
Address for correspondence: Thierry P. 
Jauniaux, Department of Pathology, Veterinary 
College, University of Liege, Sart Tilman B43, 
4000 Liege, Belgium; email: t.jauniaux@
ulg.ac.be
Indigenous Dengue 
Fever, Buenos 
Aires, Argentina
To the Editor: For 2 decades 
dengue has increased in the Americas, 
with epidemic peaks every 3 to 5 years 
(1). The disease has reemerged in 3 
South American countries bordering 
Argentina, namely, Bolivia, Brazil, 
and Paraguay. 
Argentina had remained free from 
dengue for >80 years before the dis-
ease was reintroduced in 1998 (2) as 
a consequence of insufﬁ  cient  mos-
quito control and importation of cases 
from disease-epidemic areas. Since 
then, indigenous dengue circulation 
has only been reported in the northern 
provinces of the country, which are 
close to endemoepidemic countries. 
However, the principal dengue vec-
tor, the Aedes aegypti mosquito,, has 
spread southward to latitude 35°S near 
Buenos Aires (3). 
We describe what might be the 
southernmost indigenous case of 
dengue fever documented in South 
America; this case occurred in 2007, 
an epidemic peak year for the disease 
on this continent (1). The patient was 
a pneumonologist who worked part-
time at Muñiz Hospital, a referral 
infectious diseases treatment center 
in the Buenos Aires Federal District. 
She also provided healthcare at an 
outpatient clinic in Lanus, her town of 
residence, a suburb 6 km south of the 
Federal District. Febrile illness started 
suddenly in February 2007, midsum-
mer season in Argentina. On day 5 of 
illness, fever was replaced by a short-
lived rash and itching followed by as-
thenia and nausea that persisted for 2 
days. The patient had not traveled or 
been accidentally exposed to patients’ 
blood during the previous weeks. She 
had never been vaccinated against yel-
low fever. Dengue fever was only sus-
pected retrospectively. 
Serologic results provided sup-
portive evidence of a recent dengue 
infection i.e., presence of immuno-
globulin M, as determined by  anti-
body-capture enzyme immunoassay, 
and immunoglobulin G seroconversion 
by 90% plaque reduction neutraliza-
tion test on Vero cells (4). As shown in 
the Table, dengue virus serotype 3 was 
identiﬁ  ed, and antibody results were 
negative for 3 other ﬂ  aviviruses. Thus, 
this case fulﬁ  ls Pan American Health 
Organization criteria for the diagnosis 
of dengue fever (5). Household con-
tacts were seronegative. 
For several years, conditions have 
been set for dengue virus circulation in 
Buenos Aires’ urban and suburban ar-
eas because of the abundance of mos-
quitoes and disease in persons recently 
returning from neighboring countries. 
Risk for vector transmission is highest 
in the peripheral quarters of the city 
and towards late summer (6). Besides, 
Buenos Aires, like other Latin Ameri-
can metropolitan areas, is undergoing 
demographic changes that convey fur-
ther risk for mosquito-borne disease 
transmission, namely, accelerated 
population growth mainly caused by 
informal settlements, deﬁ  cient public 
health infrastructure and basic ser-
vices, unregulated immigration from 
neighboring countries, and increased 
international mobility especially in or 
from neighboring countries (1). 
Only imported dengue cases have 
been previously documented in Bue-
nos Aires (2). According to ofﬁ  cial in-
formation, all 158 cases conﬁ  rmed by 
antibody conversion in Buenos Aires 
Federal District and Province during 
2007 were also imported (7). Of these, 
50 occurred in the southern suburban 
district where our patient lives and 
works. In the summer of 2007, dengue 
infection was mainly introduced into 
the area by Paraguayan natives living 
in Buenos Aires who had recently vis-
ited their homeland. Dengue 3 serotype 
conversion was demonstrated in most 
of the cases investigated by plaque re-
duction neutralization assay, except for 
a few cases imported from Brazil, in 
which dengue 1 serotype was detected. 
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